Project Grant R01CA301049
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$344K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $584,872 to the Fred Hutchinson Cancer Center (doing business as the Seattle Cancer Care Alliance) to conduct research aimed at understanding and targeting genomic instability in myelodysplastic syndromes (MDS).
The research under this 5-year grant seeks to elucidate the molecular mechanisms underlying the sensitivity of MDS cells with RNA splicing mutations to...
This federal Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), provides $400,000 to Syntrix Biosystems Inc. to conduct a dose expansion study of SX-682, both alone and in combination with decitabine, in patients with myelodysplastic syndromes (MDS). MDS is a precursor to acute myeloid leukemia (AML), and current treatments have suboptimal response rates and limited durability. This study aims to explore novel...
This $553,041 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to investigate the role of the MYC-alarmin axis as a potential therapeutic vulnerability in myelofibrosis, an aggressive form of blood cancer.
The five-year research project aims to assess the preclinical activity of pharmacologic agents targeting the MYC-S100A9 pathway, evaluate the...
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $444,952 in funding to the University of California, San Diego (UCSD) to explore the impact of base deaminase deregulation on the evolution of precancerous cells to acute myeloid leukemia.
The primary objective is to elucidate the relative roles of the APOBEC3C and ADAR1 base deaminases in driving the transformation of pre-leukemic stem cells (pre-LSCs) to leukemic stem...
This Project Grant award of $1,354,522 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to develop new therapies for therapy-related myeloid neoplasms (TMNs), including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), which can occur in ovarian cancer patients receiving PARP inhibitor treatment.
The research team at Mayo Clinic, the prime awardee, will 1) define the mechanisms by which replication checkpoint...
The National Cancer Institute awarded a $378,674 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The University of Texas MD Anderson Cancer Center (MD Anderson) to develop a small-molecule inhibitor of the EIF2AK1 protein kinase. The goal is to overcome ineffective erythropoiesis, or impaired red blood cell production, in patients with myelodysplastic syndromes (MDS) characterized by mutations in the SF3B1 gene. This novel therapeutic approach aims to address the severe anemia and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,398,552 to Avantgen Inc., a San Diego-based biotechnology company, to conduct preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The research aims to advance this therapeutic approach closer to clinical proof-of-concept studies, addressing the significant unmet medical need...
The National Cancer Institute (NCI) awarded a $458,698 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Regents of the University of Michigan. The grant, titled "Genes Regulating Stem and Progenitor Cell Expansion and Relapse in Acute Myeloid Leukemia", aims to study novel genes that influence normal and leukemic stem/progenitor cell expansion, and their contributions to therapy resistance and relapse in acute myeloid leukemia (AML). The 5-year project...
This $647,398 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop novel, non-invasive magnetic resonance imaging (MRI) biomarkers to assess the efficacy of new molecularly targeted therapies for myelofibrosis, a fatal blood cancer. The 5-year project will leverage advanced MRI techniques including Dixon, diffusion-weighted imaging, and magnetization transfer imaging to quantify changes in bone marrow...
This $426,306 Project Grant awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), supports research under the Cancer Treatment Research program (CFDA 93.395) to investigate a novel mechanism for eradicating leukemia stem cells in chronic myeloid leukemia (CML).
The research team at Baylor College of Medicine aims to validate the DYRK2 protein as a critical regulator of leukemia stem cell self-renewal and survival, with the goal of developing targeted...